Earnings Summary

Janux Therapeutics Inc’s revenue fell -38.87% since last year same period to $1.25Mn in the Q1 2024. On a quarterly growth basis, Janux Therapeutics Inc has generated -49.13% fall in its revenue since last 3-months.

Janux Therapeutics Inc’s net profit jumped 15.46% since last year same period to $-14.76Mn in the Q1 2024. On a quarterly growth basis, Janux Therapeutics Inc has generated -25.53% fall in its net profits since last 3-months.

Janux Therapeutics Inc’s net profit margin fell -38.29% since last year same period to -1178.91% in the Q1 2024. On a quarterly growth basis, Janux Therapeutics Inc has generated -146.75% fall in its net profit margins since last 3-months.

Janux Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.33 - a 19.51% jump from last quarter’s estimates.

Janux Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.33.

Janux Therapeutics Inc’s earning per share (EPS) jumped 28.57% since last year same period to -0.3 in the Q1 2024. This indicates that the Janux Therapeutics Inc has generated 28.57% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Janux Therapeutics Inc’s return on assets (ROA) stands at -0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Janux Therapeutics Inc’s return on equity (ROE) stands at -0.12.